LY3200882 (60 mg/kg; oral gavage; twice a day; for 21 days; BALB/C female mice) treatment significantly delays tumor growth in CT26 model[2].
LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion[1].
LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)[1].
| Animal Model: | BALB/C female mice (5-8-week-old) injected with CT26 cells[2] |
| Dosage: | 60 mg/kg |
| Administration: | Oral gavage; twice a day; for 21 days |
| Result: | A statistically significant tumor growth delay in CT26 model was observed.
|